Silence Therapeutics (SLN) Cash & Current Investments (2018 - 2026)

Silence Therapeutics (SLN) has 9 years of Cash & Current Investments data on file, last reported at $134.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 35.37% year-over-year to $134.5 million; the trailing twelve-month figure through Mar 2026 stood at $134.5 million (down 35.37% YoY), and the FY2025 full-year result was $85.1 million, down 54.26% from the prior year.
• Cash & Current Investments improved to $134.5 million in Q1 2026, from $85.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $208.1 million in Q1 2025 to a low of $64.3 million in Q4 2022.
• A 5-year average of $122.7 million and a median of $118.3 million in 2025 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments surged 177.47% in 2024 and tumbled 54.26% in 2025, its largest moves.
• Tracing SLN's Cash & Current Investments over 5 years: stood at $64.3 million in 2022, then increased by 4.3% to $67.1 million in 2023, then surged by 177.47% to $186.1 million in 2024, then plunged by 54.26% to $85.1 million in 2025, then jumped by 58.05% to $134.5 million in 2026.
• Business Quant data shows SLN's Cash & Current Investments at $134.5 million in Q1 2026, $85.1 million in Q4 2025, and $122.4 million in Q3 2025.